Cell-Free DNA Tumor Fraction in the Aqueous Humor Is Associated With Therapeutic Response in Retinoblastoma Patients

Ashley Polski, Liya Xu, Rishvanth K Prabakar, Jonathan W Kim, Rachana Shah, Rima Jubran, Peter Kuhn, David Cobrinik, James Hicks, Jesse L Berry, Ashley Polski, Liya Xu, Rishvanth K Prabakar, Jonathan W Kim, Rachana Shah, Rima Jubran, Peter Kuhn, David Cobrinik, James Hicks, Jesse L Berry

Abstract

Purpose: The aqueous humor (AH) liquid biopsy enables in vivo evaluation of tumor-derived cell-free DNA (cfDNA) from retinoblastoma (RB) eyes. Herein, we test our hypothesis that longitudinal dynamics of AH cfDNA-including tumor fraction (TFx) and somatic copy number alteration (SCNA) amplitude-correspond to therapeutic response.

Methods: Eyes with ≥3 AH extractions during intravitreal chemotherapy (IVM) or at secondary enucleation between 2015 to 2019 were included. AH cfDNA was sequenced to assess RB SCNA amplitude; ichorCNA software was used to estimate TFx. Eyes without SCNAs or with TFx < 0.10 across all samples were excluded. Therapeutic responses for each eye were determined from clinical records. Statistical analyses included Mann-Whitney U and Pearson correlation tests.

Results: Twenty eyes of 20 patients underwent ≥3 AH extractions; 6 eyes lacked SCNAs or had TFx < 0.10 throughout sampling and were excluded. Clinical progression was associated with significantly higher SCNA amplitudes and TFx values than regression (P ≤ 0.04). Relative increases in TFx (ΔTFx 1.86 ± 2.22) were associated with disease progression, whereas relative decreases in TFx (ΔTFx 0.53 ± 0.36) were associated with disease regression (P < 0.00001). A ≥15% increase in TFx relative to baseline during treatment was associated with an over 90-fold increased likelihood of clinical progression (odds ratio = 90.67, 95% confidence interval = 8.30-990.16, P = 0.0002). TFx and SCNA amplitude were significantly positively correlated throughout sampling (P ≤ 0.002).

Conclusions: Longitudinal changes in AH-derived cfDNA TFx and SCNA amplitude are concordant with clinical responses of intraocular RB during active therapy.

Translational relevance: Longitudinal evaluation of AH cfDNA may provide an objective, quantitative way to monitor therapeutic response and disease burden in RB patients.

Keywords: aqueous humor; liquid biopsy; retinoblastoma; somatic copy number alteration; tumor fraction.

Conflict of interest statement

Disclosure: A. Polski, None; L. Xu, Aqueous Humor Cell Free DNA for Diagnostic and Prognostic Evaluation of Ophthalmic Disease (P); R.K. Prabakar, None; J.W. Kim, None; R. Shah, None; R. Jubran, None; P. Kuhn, None; D. Cobrinik, None; J. Hicks, Aqueous Humor Cell Free DNA for Diagnostic and Prognostic Evaluation of Ophthalmic Disease (P); J.L. Berry, Aqueous Humor Cell Free DNA for Diagnostic and Prognostic Evaluation of Ophthalmic Disease (P)

Copyright 2020 The Authors.

Figures

Figure 1.
Figure 1.
SCNA amplitude and TFx values correspond to clinical therapeutic response. (A) Genomic profiles of six sequential AH samples extracted from a single eye (case 42) during IVM therapy for tumor seeding (* = 6p gain or 16q loss). (B) Changes in SCNA amplitude correspond to clinical regression (R) and progression (P) at each sampling timepoint. (C) Changes in TFx correspond to clinical regression (R) and progression (P) at each sampling timepoint. (D) Fundus photographs of the affected eye over the course of 6 injections of IVM. Reduction of vitreous seeding and tumor size occurred between injections 2 through 5, whereas a large recurrence of the retinal tumor (arrow) was noted on the day of injection 6.
Figure 2.
Figure 2.
Genomic profiles showing SCNAs from cell-free DNA in the aqueous humor of an eye with retinoblastoma (case 12). The genomic profiles generated by our established SCNA analysis protocol (A) were concordant with the genomic profiles generated by the ichorCNA pipeline (B). In ichorCNA profiles, the color of each data point corresponds to estimated integer copy number (green = 1 copy, blue = 2 copies, brown = 3 copies, red = 4+ copies).
Figure 3.
Figure 3.
SCNA absolute amplitudes and corresponding TFx for cases 6 (A), 13 (B), 40 (C), and 12 (D). Both SCNA gains and losses are represented as absolute values, determined by |1 – ratio to the median|, for visualization purposes. Clinical progression (P) or regression (R) at each sampling timepoint is shown.
Figure 4.
Figure 4.
TFx and SCNA absolute amplitudes from aqueous humor cell-free DNA are significantly positively correlated via Pearson correlation. Specifically, TFx was correlated with amplitudes of 6p gain (r(46) = 0.685, P < 0.00001), 1q gain (r(40) = 0.763, P < 0.00001), 16q loss (r(33) = 0.800, P < 0.00001), and 2p gain (r(23) = 0.588, P = 0.002). Values are shown as absolute amplitude irrespective of a gain or loss.

References

    1. Shields JA, Shields CL, Ehya H, Eagle RC, De Potter P. Fine-needle aspiration biopsy of suspected intraocular tumors. The 1992 Urwick Lecture. Ophthalmology. 1993; 100: 1677–1684.
    1. Karcioglu ZA. Fine needle aspiration biopsy (FNAB) for retinoblastoma. Retina. 2002; 22: 707–710.
    1. Karcioglu ZA, Gordon RA, Karcioglu GL. Tumor seeding in ocular fine needle aspiration biopsy. Ophthalmology. 1985; 92: 1763–1767.
    1. Eide N, Syrdalen P, Walaas L, Hagmar B. Fine needle aspiration biopsy in selecting treatment for inconclusive intraocular disease. Acta Ophthalmol Scand. 1999; 77: 448–452.
    1. Eide N, Walaas L.. Fine-needle aspiration biopsy and other biopsies in suspected intraocular malignant disease: a review. Acta Ophthalmol. 2009; 87: 588–601.
    1. Eriksson O, Hagmar B, Ryd W. Effects of fine-needle aspiration and other biopsy procedures on tumor dissemination in mice. Cancer. 1984; 54: 73–78.
    1. Ali MJ, Honavar SG, Vemuganti GK, Singh AD. Fine needle aspiration biopsy of retinal tumors. Monogr Clin Cytol. 2012; 21: 72–81.
    1. Berry JL, Xu L, Kooi I, et al. .. Genomic cfDNA analysis of aqueous humor in retinoblastoma predicts eye salvage: the surrogate tumor biopsy for retinoblastoma. Mol Cancer Res. 2018; 16: 1701–1712.
    1. Berry JL, Xu L, Murphree AL, et al. .. Potential of aqueous humor as a surrogate tumor biopsy for retinoblastoma. JAMA Ophthalmol. 2017; 135: 1221–1230.
    1. Berry JL, Xu L, Polski A, et al. .. Aqueous humor is superior to blood as a liquid biopsy for retinoblastoma. Ophthalmology. 2020; 127: 552–554.
    1. Lianidou E, Pantel K. Liquid biopsies. Genes Chromosomes Cancer. 2019; 58: 219–232.
    1. Choudhury AD, Werner L, Francini E, et al. .. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018; 3: e122109.
    1. Chen X, Chang CW, Spoerke JM, et al. .. Low-pass whole-genome sequencing of circulating cell-free DNA demonstrates dynamic changes in genomic copy number in a squamous lung cancer clinical cohort. Clin Cancer Res. 2019; 25: 2254–2263.
    1. Oellerich M, Schütz E, Beck J, et al. .. Using circulating cell-free DNA to monitor personalized cancer therapy. Crit Rev Clin Lab Sci. 2017; 54: 205–218.
    1. Tissot C, Toffart AC, Villar S, et al. .. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J. 2015; 46: 1773–1780.
    1. Stover DG, Parsons HA, Ha G, et al. .. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 2018; 36: 543–553.
    1. Berry JL, Jubran R, Kim JW, et al. .. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer. 2013; 60: 688–693.
    1. Berry JL, Shah S, Bechtold M, Zolfaghari E, Jubran R, Kim JW. Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer. 2017; 64.
    1. Munier FL, Soliman S, Moulin AP, Gaillard MC, Balmer A, Beck-Popovic M. Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. Br J Ophthalmol. 2012; 96: 1084–1087.
    1. Baslan T, Kendall J, Rodgers L, et al. .. Genome-wide copy number analysis of single cells. Nat Protoc. 2012; 7: 1024–1041.
    1. Baslan T, Kendall J, Rodgers L, et al. .. Corrigendum: Genome-wide copy number analysis of single cells. Nat Protoc. 2016; 11: 616.
    1. Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer. 2007; 46: 617–634.
    1. Adalsteinsson VA, Ha G, Freeman SS, et al. .. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017; 8: 1324.
    1. Murphree A.L. The case for a new group classification of intraocular retinoblastoma. Ophthalmol Clin North Am. 2005; 18: 41–53.
    1. Mallipatna A., et al. . In: Amin MB, Edge SB, Greene FL, eds. AJCC Cancer Staging Manual Vol. 8th Edition. Ch. 68, Springer; 2017: 819–831.
    1. Ghassemi F, Amoli FA.. Pathological findings in enucleated eyes after intravitreal melphalan injection. Int Ophthalmol. 2014; 34: 533–540.
    1. Rushlow DE, Mol BM, Kennett JY, et al. .. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 2013; 14: 327–334.
    1. Gerrish A, Stone E, Clokie S, et al. .. Non-invasive diagnosis of retinoblastoma using cell-free DNA from aqueous humour. Br J Ophthalmol. 2019; 103: 721–724.

Source: PubMed

3
Subscribe